Montreal Cognitive Assessment as a screening instrument for cognitive impairments in schizophrenia

Yang, Zixu; Rashid, Nur Amirah Abdul; Quek, Yue Feng; Lam, Max; See, Yuen Mei; Maniam, Yogeswary; Dauwels, Justin; Tan, Bhing Leet; Lee, Jimmy

doi:10.1016/j.schres.2018.03.008

Cited by 48 publications

(32 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Impairments in executive, visual and spatial functions will be measured with the Montreal Cognitive Assessment scale (MoCA); scores of 26 points or higher represent normal cognitive functioning. One point will be added when the academic level is less than 12 years, in agreement with other authors 11…”

Section: Methods and Analysissupporting

confidence: 77%

<p>Association between mitochondrial DNA and cognitive impairment in schizophrenia: study protocol for a Mexican population</p>

Cruz

Juárez‐Rojop

Tovilla-Zárate

et al. 2019

NDT

View full text Add to dashboard Cite

Background Circulating cell-free mitochondrial DNA (cf-mtDNA) fragments in blood plasma have been reported in patients with schizophrenia (SZ). Although the relationship of cf-mtDNA to the cognitive status of patients with SZ has not yet been explored, it is known that cognitive impairment in SZ compromises the functional and social capacity of these patients and diminishes their quality of life. In this sense, the assessment of the severity of cognitive impairment in a Mexican population with SZ and its association with cf-mtDNA levels in blood plasma may provide the possibility of using cf-mtDNA as a biomarker to determine the status of the disease and the possible ensuing changes over time. Methods Subjects for a case–control study will be recruited. cf-mtDNA obtained from blood plasma will be quantified by real-time polymerase chain reaction, using melting curve technology with SYBR green as amplification marker. Patients with SZ will be grouped into those with severe, mild, and no cognitive impairment according to Montreal Cognitive Assessment scale scores, to determine differences between cognitive performance and cf-mtDNA levels in blood plasma. Ethics and communication This study has been approved by the ethics and investigation committees of the High Specialty Regional Hospital of Mental Health (Hospital Regional de Alta Especialidad de Salud Mental); project No. HRAESM/DG/RP/1128/2018. We plan to communicate our research findings in scientific conferences and in peer-reviewed journals. Conclusion It is known that cognitive dysfunction provokes negative effects in an SZ patient´s life. This project aims to provide better knowledge about the role of cf-mtDNA in the pathogenesis of cognitive impairment in SZ, as an attempt to achieve improvements to the existing treatments, thereby helping to prevent major cognitive deterioration.

show abstract

Section: Methods and Analysissupporting

confidence: 77%

<p>Association between mitochondrial DNA and cognitive impairment in schizophrenia: study protocol for a Mexican population</p>

Cruz

Juárez‐Rojop

Tovilla-Zárate

et al. 2019

NDT

View full text Add to dashboard Cite

show abstract

“…The MoCA has proven to be a sensitive tool for screening patients with other forms of dementia, such as vascular dementia (Freitas, Simoes, Alves, Vicente, & Santana, 2012), dementia associated with Parkinson's disease (Hoops et al, 2009) and Frontotemporal Dementia (Freitas, Simoes, Alves, Duro, & Santana, 2012). In psychiatric practice, the MoCA has been used successfully to evaluate cognitive impairment in patients with depression, BD and schizophrenia (Musso, Cohen, Auster, & McGovern, 2014;Yang et al, 2018) as well as depressed patients undergoing electroconvulsive therapy (ECT) (Moirand et al, 2018). For these reasons, the MoCA was implemented in our daily clinical practice as a systematic cognitive screening tool.…”

Section: Psychopathological Assessmentmentioning

confidence: 99%

Duration of untreated illness and depression severity are associated with cognitive impairment in mood disorders

Galimberti

Bosi

Volontè

et al. 2020

International Journal of Psychiatry in Clinical Practice

View full text Add to dashboard Cite

Introduction: In this study we estimated the rate and the trajectory of cognitive impairment in a naturalistic sample of outpatients with major depressive disorder (MDD) and bipolar disorder (BD) and its correlation with different variables. Materials and methods: An overall sample of 109 outpatients with MDD or BD was assessed for multiple clinical variables, including duration of untreated illness (DUI), and tested using the Montreal Cognitive Assessment (MoCA) during Major Depressive Episodes (MDE) and after remission. Correlations between MoCA scores and the clinical variables were then computed. Results: About 50% of patients with MDD and BD showed mild cognitive impairment during MDE. Improvement of cognitive function between depression and remission was significant, even though residual symptoms were observed especially in the most impaired patients. Of note, cognitive performance during depression was negatively associated with depression severity and DUI. Discussion: Present findings confirm available evidence about patterns of cognitive impairment in mood disorders, in terms of prevalence and persistence beyond remission in most severe cases. Moreover, a longer DUI was associated with worse cognitive performance during depression, and consequently with poorer outcome, underlining the importance of prompt treatment of these disorders also in light of a cognitive perspective.

show abstract

“…The MoCA has proven to be a sensitive tool for screening patients with other forms of dementia, such as vascular dementia, 45 dementia associated with Parkinson's disease, 46 and finally frontotemporal dementia. 47 With respect to psychiatric disorders, the MoCA has been used successfully to evaluate cognitive impairment in patients with depression, BD, and schizophrenia 48,49 as well as in depressed patients undergoing ECT. 50…”

Section: Cognitive Screening: the Mocamentioning

confidence: 99%

Using network analysis to explore cognitive domains in patients with unipolar versus bipolar depression: a prospective naturalistic study

Galimberti¹,

Bosi

Caricasole

et al. 2019

CNS Spectr.

View full text Add to dashboard Cite

Objective: Despite growing evidence in the field of cognitive function in mood disorders, the neurocognitive profiles of patients with unipolar and bipolar depression still need further characterization. In this study, we applied network analysis, hypothesizing this approach could highlight differences between Major Depressive Disorder (MDD) and Bipolar Disorder (BD) from a cognitive perspective. Methods: The cognitive performance of 109 patients (72 unipolar and 37 bipolar depressed outpatients) was assessed through the Montreal Cognitive Assessment (MoCA) and a series of clinical variables was collected. Differences in cognitive performance between MDD and BD patients were tested using non parametric tests. Moreover, a network graph representing MoCA domains as nodes and Spearman's rho correlation coefficients between the domains as edges was constructed for each group. Results: The presence of mild cognitive impairment was observed both in MDD and BD patients during depression. No statistical significant difference was found between the two groups in terms of overall cognitive performance and across single domains. Nonetheless, network analytic metrics demonstrated different roles of memory and executive dysfunction in MDD vs BD patients: in particular, MDD network was more densely interconnected than BD network and memory was the node with the highest betweenness and closeness centrality in MDD, while executive function was more central in BD. Conclusions:From a network analytic perspective, memory impairment displays a central role in the cognitive impairment of patients with unipolar depression, whereas executive dysfunction appears to be more central in bipolar depression. Further research is warranted to confirm our results.

show abstract

Montreal Cognitive Assessment as a screening instrument for cognitive impairments in schizophrenia

Abstract: These findings indicate that MoCA is a useful bedside cognitive screening instrument for people with schizophrenia.

Cited by 48 publications

References 29 publications

<p>Association between mitochondrial DNA and cognitive impairment in schizophrenia: study protocol for a Mexican population</p>

<p>Association between mitochondrial DNA and cognitive impairment in schizophrenia: study protocol for a Mexican population</p>

Duration of untreated illness and depression severity are associated with cognitive impairment in mood disorders

Using network analysis to explore cognitive domains in patients with unipolar versus bipolar depression: a prospective naturalistic study

Contact Info

Product

Resources

About